Y-Intercept (HK)’s Intellia Therapeutics NTLA Stock Holding History

Y-Intercept (HK)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$607K	Sell	35,846 -105,235	-75%	-$1.47M	0.01%	1253
2026 Q1	$1.81M	Buy	+141,081	New	+$1.8M	0.03%	764
2025 Q4	–	Sell	-137,290	Closed	-$2.37M	–	1865
2025 Q3	$2.37M	Buy	+137,290	New	+$1.69M	0.06%	514
2025 Q1	–	Sell	-26,071	Closed	-$304K	–	1494
2024 Q4	$304K	Buy	+26,071	New	+$407K	0.02%	932

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Y-Intercept (HK)'s NTLA Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Intellia Therapeutics (NTLA) stake by 75% in Q2 2026, selling an estimated $1.47M and leaving 35,846 shares worth $607K. The position accounts for 0.01% of the portfolio, ranked #1253.

Y-Intercept (HK) first reported a position in NTLA in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.37M in Q3 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Y-Intercept (HK) held 35,846 shares of Intellia Therapeutics worth $607K as of Q2 2026.
Y-Intercept (HK) sold 105,235 Intellia Therapeutics shares in Q2 2026, an estimated $1.47M.
Intellia Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1253 holding.
Y-Intercept (HK) first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 4 quarters since.
Y-Intercept (HK)'s Intellia Therapeutics position peaked at $2.37M in Q3 2025.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.